



WEB ANNOUNCEMENT

Rapid Response Partnership Vehicle (RRPV) Program Makes First Awards for Biothreat Diagnostics under MedTech Focus Area

Summerville, SC – November 27, 2024

The Rapid Response Partnership Vehicle (RRPV) consortium today announces the first awards made for the Diagnostics Rapid Response Initiative (DxR2), a biothreat diagnostics program that is part of the broader Medical Technology (MedTech) focus area which supports development of medical tools, equipment, and devices to diagnose diseases caused by biothreats.

These project awards mark a significant milestone in the Biomedical Advanced Research and Development Authority's ([BARDA](#)'s) mission to accelerate the research and development of future medical countermeasure (MCM) products. *Optimization of the AMD Plus Diagnostic Test for Melioidosis Rapid Biothreat Response* has been awarded to [InBios International, Inc.](#) and *Development of a Marburg Rapid Antigen Test* has been awarded to [OraSure Technologies, Inc.](#)

The awards will facilitate rapid development and manufacturing preparedness for diagnostics that address high-priority biothreats.

In support of BARDA's DxR2 program, the RRPV forms long-term partnerships with domestic diagnostic test manufacturers to prepare for and have the capability to pivot rapidly in response to high-priority biothreats.

Each partner will establish a rapid response program in lieu of stockpiling so that products ship within days to weeks after being ordered and to achieve the equivalent of stockpiling of multiple infectious disease tests in one capability. This capability includes advanced assay development, production, inventory planning, and supply chain capabilities to develop, manufacture and deliver biothreat tests at multiple scales within the timelines outlined in the National Biodefense Strategy ([NBS](#)). In addition, the capability could be repurposed to develop and produce tests for response to other biological incidents when needed.



The *Optimization of the AMD Plus Diagnostic Test for Melioidosis Rapid Biothreat Response* award to InBios International, Inc. in the amount of \$16.5 million aims to build on the existing Active Melioidosis Detect™ Plus (AMD Plus) device design with the goal to finalize the operational workflow and test algorithm, and obtain FDA clearance for identification of capsular polysaccharide (CPS) in patients with *Burkholderia pseudomallei* (Bp) infection.

The *Development of a Marburg Rapid Antigen Test* award to OraSure Technologies, Inc. in the amount of \$7.5 million in the base period with the potential value up to \$11 million for development, design transfer, manufacturing, and FDA clearance of the OraSure Marburg rapid test to enable production-ready capacity by leveraging their existing manufacturing capability including processes, equipment, and facilities. The development of a biothreat rapid test, specifically to the Marburg virus, through to commercialization will support the Government acceleration of medical countermeasure products to build a diagnostic portfolio and rapid response manufacturing capability to produce tests at scale when needed.

“These projects are the first in a diagnostic portfolio that will enable rapid development and manufacturing capabilities for diagnostics that address high-priority biothreats,” said Mike Stebbins, PhD, Sr. VP for Medical & Threat Countermeasures at Advanced Technology International (ATI). “We are honored to support BARDA in fortifying national healthy security by accelerating technology development to address emerging infectious diseases.”

For more information about the RRPV program and upcoming opportunities, please visit <https://www.rrpv.org/>.

The views expressed in this news release/article are those of the authors and may not reflect the official policy or position of the Department of Health and Human Services, ASPR or BARDA.

About Rapid Response Partnership Vehicle

The RRPV is a 10-year, multi-purpose program designed to support medical countermeasures, such as vaccines, therapeutics, and medical technology products from early-stage development through advanced development, procurement, sustainment, and commercialization, including manufacturing infrastructure development. The Rapid Response Partnership Vehicle is managed by [Advanced Technology International](#).